子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 有机电致发光化合物以及包含其的有机电致发光材料和有机电致发光装置 | CN201580050211.9 | 2015-09-25 | CN107074764A | 2017-08-18 | 文斗铉; 梁正恩; 姜熙龙; 林永默; 全志松; 安熙春; 洪镇理; 李琇炫; 金宾瑞; 李泰珍 |
| 本公开涉及有机电致发光化合物以及包含其的有机电致发光材料和有机电致发光装置。本公开的有机电致发光化合物具有极佳的色彩纯度、溶解性和热稳定性。通过包含本公开的有机电致发光化合物和有机电致发光材料，可提供展示出低驱动电压、极佳电流效率和功率效率和显著改进的寿命的有机电致发光装置。 | ||||||
| 2 | 作为mGluR5拮抗剂的吡嗪－2－甲酰胺衍生物 | CN200680007159.X | 2006-03-02 | CN101208311A | 2008-06-25 | G·杰什科; S·科茨威斯基; R·H·P·波特; E·维埃拉 |
| 本发明涉及用作代谢型谷氨酸受体拮抗剂的通式(I)的新型吡嗪2－甲酰胺衍生物，中R1、R2和R3如本说明书和权利要求书中定义的。 | ||||||
| 3 | 用于治疗CNS疾病的芳基磺酰胺 | CN201180044733.X | 2011-09-16 | CN103108864A | 2013-05-15 | M·科瓦奇科夫斯基; P·科瓦尔斯基; J·亚希科夫斯卡; M·马尔钦科夫斯卡; K·米特卡; A·布茨基; A·韦索沃夫斯卡; M·帕沃夫斯基 |
| 本发明涉及式(I)的芳基磺酰胺及其药用可接受的盐。所述化合物可用于治疗和/或预防中枢神经系统的紊乱。 | ||||||
| 4 | 光致抗蚀剂组合物 | CN201110038475.6 | 2011-02-14 | CN102162995A | 2011-08-24 | 增山达郎; 山口训史 |
| 本发明提供一种光致抗蚀剂组合物，所述的光致抗蚀剂组合物含有：包含由式(IA)表示的阴离子的锍盐，其中R1和R2独立地表示氢原子、C1-C12脂族烃基、C3-C20饱和环烃基、C6-C20芳族烃基或C7-C21芳烷基，并且所述脂族烃基、所述饱和环烃基、所述芳族烃基和所述芳烷基可以具有一个或多个选自由羟基、氰基、氟原子、三氟甲基和硝基组成的组中的取代基，并且所述脂族烃基中的一个或多个-CH2-可以被-O-或-CO-代替，或R1和R2相互结合以与它们连接的氮原子一起形成C4-C20含氮环；丙烯酸类树脂，其具有酸不稳定基团，并且不溶或难溶于碱性水溶液，但是通过酸的作用变得可溶于碱性水溶液；和酸生成剂。 | ||||||
| 5 | 用于治疗雄激素依赖性疾病的3型17β-羟基类固醇脱氢酶抑制剂 | CN02817250.7 | 2002-09-05 | CN1551878B | 2011-08-10 | T·J·古兹; K·帕鲁克; A·K·马拉姆斯; J·D·里维拉; R·J·多尔; V·M·吉里亚瓦拉布汗; J·帕克特尔; 刘义君; A·K·萨克塞纳 |
| 本发明公开了式(I)化合物、其前体药物、或者所述化合物或所述前体药物的药学上可接受的盐，它们用作3型17β-羟基类固醇脱氢酶抑制剂。本发明还公开了包含所述化合物的药用组合物以及它们在治疗或预防雄激素依赖性疾病方面的应用。 | ||||||
| 6 | 含苯磺酰基的选择性雌激素受体调节剂 | CN03817201.1 | 2003-07-16 | CN1668303B | 2010-10-27 | R·D·达利; J·A·多奇; S·A·弗兰克; S·A·琼斯; T·A·谢菲尔德; O·B·华莱士; K·C·冯; C·W·胡梅尔; G·S·路易斯 |
| 本发明涉及一种选择性雌激素受体调节剂，即式I化合物或其药用酸加成盐，所述化合物或其药用酸加成盐可用于例如治疗子宫内膜异位症和/或子宫平滑肌瘤/子宫肌瘤。 | ||||||
| 7 | 用于治疗雄激素依赖性疾病的3型17β－羟基类固醇脱氢酶抑制剂 | CN02817250.7 | 2002-09-05 | CN1551878A | 2004-12-01 | T·J·古兹; K·帕鲁克; A·K·马拉姆斯; J·D·里维拉; R·J·多尔; V·M·吉里亚瓦拉布汗; J·帕克特尔; 刘义君; A·K·萨克塞纳 |
| 本发明公开了式(I)化合物、其前体药物、或者所述化合物或所述前体药物的药学上可接受的盐，它们用作3型17β－羟基类固醇脱氢酶抑制剂。本发明还公开了包含所述化合物的药用组合物以及它们在治疗或预防雄激素依赖性疾病方面的应用。 | ||||||
| 8 | 取代的苯并噻吩基衍生物作为用于治疗II型糖尿病的GPR40激动剂 | CN201580066945.6 | 2015-10-08 | CN107001281A | 2017-08-01 | 郭纪鸿; M.R.普拉耶; S-M.杨; 章越梅; 黄辉 |
| 本发明公开了用于治疗受GPR40受体调节影响的障碍的化合物、组合物和方法。此类化合物由式(I)表示，其中R1、R2、R3、R5、R6、W和A在本文中定义。 | ||||||
| 9 | 用于治疗CNS疾病的芳基磺酰胺 | CN201410638124.2 | 2011-09-16 | CN104529999A | 2015-04-22 | M·科瓦奇科夫斯基; P·科瓦尔斯基; J·亚希科夫斯卡; M·马尔钦科夫斯卡; K·米特卡; A·布茨基; A·韦索沃夫斯卡; M·帕沃夫斯基 |
| 本发明涉及式(I)的芳基磺酰胺及其药用可接受的盐。所述化合物可用于治疗和/或预防中枢神经系统的紊乱。 | ||||||
| 10 | 作为mGluR5拮抗剂的吡嗪-2-甲酰胺衍生物 | CN200680007159.X | 2006-03-02 | CN101208311B | 2013-06-12 | G·杰什科; S·科茨威斯基; R·H·P·波特; E·维埃拉 |
| 本发明涉及用作代谢型谷氨酸受体拮抗剂的通式(I)的新型吡嗪2-甲酰胺衍生物：其中R1、R2和R3如本说明书和权利要求书中定义的。 | ||||||
| 11 | 11-βHSD1抑制剂 | CN200780008840.0 | 2007-02-07 | CN101400653A | 2009-04-01 | J·S·向; E·萨亚; S·Y·塔姆; J·C·麦丘; L·陈; M·伊佩克; K·李; H-Q·李; 李建昌; 李伟; T·S·曼索尔; V·苏里; R·瓦尔加斯; 吴玉川; 万兆奎; 李金波; E·比南; D·P·威尔森 |
| 本发明涉及抑制11βHSD1。 | ||||||
| 12 | 新颖的M3毒蕈碱性乙酰胆碱受体拮抗剂 | CN200480041273.5 | 2004-12-03 | CN1913895A | 2007-02-14 | 雅各布·布希-彼得森; 金坚; 傅巍; 迈克尔·R·帕洛维克 |
| 本发明提供了毒蕈碱性乙酰胆碱受体拮抗剂及其使用方法。 | ||||||
| 13 | 含苯磺酰基的选择性雌激素受体调节剂 | CN03817201.1 | 2003-07-16 | CN1668303A | 2005-09-14 | R·D·达利; J·A·多奇; S·A·弗兰克; S·A·琼斯; T·A·谢菲尔德; O·B·华莱士; K·C·冯; C·W·胡梅尔; G·S·路易斯 |
| 本发明涉及一种选择性雌激素受体调节剂，即式I化合物或其药用酸加成盐，所述化合物或其药用酸加成盐可用于例如治疗子宫内膜异位症和/或子宫平滑肌瘤/子宫肌瘤。 | ||||||
| 14 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | US15697867 | 2017-09-07 | US20170362196A1 | 2017-12-21 | Hui Huang; Gee-Hong Kuo; Mark R. Player; Shyh-Ming Yang; Yue-Mei Zhang |
| Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein. | ||||||
| 15 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | US14972333 | 2015-12-17 | US20160304450A1 | 2016-10-20 | Jun Liang; Daniel Fred Ortwine; Xiaojing Wang; Steven P. Govek; Mehmet Kahraman; Johnny Y. Nagasawa; Nicholas D. Smith; Simon Charles Goodacre; Nicholas Charles Ray |
| Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | ||||||
| 16 | Actinic-ray- or radiation-sensitive resin composition, compound and method of forming pattern using the composition | US13485793 | 2012-05-31 | US09023579B2 | 2015-05-05 | Shuhei Yamaguchi; Akinori Shibuya |
| According to one embodiment, an actinic-ray- or radiation-sensitive resin composition includes any of the compounds (A) of general formula (I) below that when exposed to actinic rays or radiation, generates an acid and a resin (B) whose rate of dissolution into an alkali developer is increased by the action of an acid. (The characters used in general formula (I) have the meanings mentioned in the description.) | ||||||
| 17 | Arylosulfonamides for the treatment of CNS diseases | US13824066 | 2011-09-16 | US08822517B2 | 2014-09-02 | Marcin Kolaczkowski; Piotr Kowalski; Jolanta Jaśkowska; Monika Marcinkowska; Katarzyna Mitka; Adam Bucki; Anna Wesolowska; Maciej Pawlowski |
| Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system. | ||||||
| 18 | ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION, COMPOUND AND METHOD OF FORMING PATTERN USING THE COMPOSITION | US12833668 | 2010-07-09 | US20110027716A1 | 2011-02-03 | Shuhei YAMAGUCHI; Akinori Shibuya |
| According to one embodiment, an actinic-ray- or radiation-sensitive resin composition includes any of the compounds (A) of general formula (I) below that when exposed to actinic rays or radiation, generates an acid and a resin (B) whose rate of dissolution into an alkali developer is increased by the action of an acid. (The characters used in general formula (I) have the meanings mentioned in the description.) | ||||||
| 19 | 11-Beta HSD1 Inhibitors | US12539232 | 2009-08-11 | US20100029648A1 | 2010-02-04 | Jason Shaoyun Xiang; Eddine Saiah; Steve Y. Tam; John C. McKew; Lihren Chen; Manus Ipek; Katherine Lee; Huan-Qiu Li; Jianchang Li; Wei Li; Tarek Suhayl Mansour; Vipin Suri; Richard Vargas; Yuchuan Wu; Zhao-Kui Wan; Jinbo Lee; Eva Binnun; Douglas P. Wilson |
| This invention relates to inhibiting 11βHSD1. | ||||||
| 20 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | US12100093 | 2008-04-09 | US20080214612A1 | 2008-09-04 | Robert Dean Dally; Jeffrey Alan Dodge; Scott Alan Frank; Scott Alan Jones; Timothy Alan Shepherd; Owen Brendan Wallace; Kin Chlu Fong; Conrad Wilson Hummel; George Sal Lewis |
| The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata. | ||||||
QQ群二维码
意见反馈
意见反馈